Vol. 22/No. 07

As investigators expand their understanding of the biology of endometrial cancer, doors to new treatment approaches are opening, including the use of a variety of combinations that employ targeted therapies and immunotherapies.

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

During the COVD-19 pandemic, the expansion of covered services for telehealth by the Centers for Medicare & Medicaid Services and private insurers has provided a safer alternative for patients and physicians.

Investigators have launched the Epidemiology of Young Lung Cancer study to identify risk factors that can help shed light on why lung cancer develops in the younger population.

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

The success of the COVID-19 vaccines based on messenger RNA has led to a surge of interest from investigators, pharmaceutical companies, and investors in similar technology for other diseases, including a number of oncology indications.

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

In the cancer arena, COVID-19 information problems highlight the critical role of clear, honest, and effective communication with the public, patients, and their families regarding the increasing complexity of a multitude of topics related to malignant disease and its management.